38 results on '"Legangneux, Eric"'
Search Results
2. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
3. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
4. Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056)
5. Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects
6. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects
7. Impact of siponimod on vaccination response in a randomized, placebo-controlled study
8. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo
9. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects
10. A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat
11. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers
12. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration
13. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
14. Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism
15. Safety, Tolerability and Pharmacodynamics of Intravenous Siponimod in Healthy Subjects (P3.399)
16. Absolute Bioavailability of Single, Oral Dose of Siponimod in Healthy Subjects (P3.402)
17. Vaccination under anti-CD20 drugs for multiple sclerosis: current knowledge and opportunities
18. [P1-051]: RESULTS FROM A 3-MONTH STUDY IN HEALTHY SUBJECTS AGED 60 YEARS WITH THE BACE INHIBITOR CNP520
19. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
20. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
21. Siponimod (BAF312) Safety, Tolerability and Pharmacodynamics in Healthy Subjects with Different Genetic Variants of the Cytochrome(P450)2C9 Enzyme (P3.032)
22. Comparison of Siponimod (BAF312) Pharmacokinetics in Healthy Subjects with Different Genetic Variants of the Cytochrome(P450)2C9 Enzyme (P3.088)
23. Effect of Siponimod Treatment on Vaccination-Induced Immune Response: A Randomized, Double-Blind, Placebo-Controlled Study (P2.080)
24. Siponimod TQT study results
25. Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects
26. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women
27. Pharmacokinetics, Safety and Tolerability of Siponimod (BAF312) in Subjects with Different Levels of Hepatic Impairment Compared to Demographically Matched Healthy Subjects (P1.135)
28. RESULTS FROM A 3-MONTH STUDY IN HEALTHY SUBJECTS AGED 60 YEARS WITH THE BACE INHIBITOR CNP520
29. Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects
30. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312), a Selective S1P1,5 Receptor Modulator, on Cardiac Repolarization: Results of a Thorough QTc (TQT) Study (P2.232)
31. No Clinically Significant Effect on Pulmonary Function Observed with Siponimod (BAF312) Alone or in Combination With Propranolol in Healthy Adult Subjects (P2.212)
32. Cardiovascular Effects of Combined Administration of Siponimod and Popranolol - Importance of Sequencing During Co -administration (P2.195)
33. Distinct effects of IPSU and suvorexant on mouse sleep architecture
34. Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism
35. A Double-blind, Placebo- and Flurazepam-controlled Investigation of the Residual Psychomotor and Cognitive Effects of Modified Release Zolpidem in Young Healthy Volunteers
36. Lack of effect of amisulpride on the pharmacokinetics and safety of lithium
37. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT 4 receptor agonist, following oral and intravenous administration
38. Metabolism and Disposition of Siponimod, a Novel Selective S1P 1 /S1P 5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.